Pure H20 Bio-Technologies, Inc. Announces New Stock Symbol PRHB, Stock Transfer Agent and Reverse Split of Its Common Stock Pure H20 Bio-Technologies, Inc. (PINK SHEETS: PRHB), today announces it duly appoints Continental Stock Transfer and Trust Company, located at 17 Battery Place, New York, New York, as the Exchange Agent for its approved reverse split of the Company's Common Stock. On November 3, 2006 the shareholders of the company approved a 1- for-1,000 (1:1,000) reverse stock split of the Company's Common Stock. The reverse split became effective today upon the filing of the company's Certificate of Amendment to the Articles of Incorporation of Pure H20 Bio-Technologies, Inc., with the Florida Secretary of State.
The reorganization will be effective at the open of the market today and the new stock symbol is "PRHB" and the Cusip Number is: 746223205. The distribution of the post-split common shares are payable upon surrender of the pre-split common shares.
"For each one thousand (1,000) shares of pre-split common stock held a shareholder will receive one (1) share of post-split common stock. No fractional shares or script representing fractions of a share shall be issued, but in lieu thereof, each fraction of a share that any Stockholder would otherwise be entitled to receive shall be rounded up to the nearest whole share and no additional script or payment made," as stated in the Company's Articles of Amendment.
About PRHB: PRHB is a publicly held company specializing in the research, development and commercialization of its unique residential, commercial and hospital water disinfection systems. The company intends to commence the manufacture and distribution of its products through a network of independent distributors.
The foregoing press release contains forward-looking statements that can be identified by such terminology as expects, potential, suggests, may, intends, or similar expressions. Such forward-looking statements involve known risks, uncertainties, and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management expectations regarding future research, development, and or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing, unexpected regulatory delays or government regulation generally, the company's ability to obtain or maintain patent and other proprietary intellectual protection, and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
News, in case anybody...you know...cares...
Pure H2O Bio-Technologies, Inc. Announces New Testing Results for Tetrasilver Tetraoxide as a Disinfectant for Major Microbial Drinking Water Contaminants
BOCA RATON, Fla., Nov 21, 2006 (BUSINESS WIRE) -- Pure H2O Bio-Technologies, Inc. (Pink Sheets:PRHB) announced today the results from three successful studies focused on potable water disinfection treatment for two major microbial threats to human health. The microorganisms, Escherichia coli (bacterium) and Cryptosporidium parvum (protozoan parasite of humans), were responsible for 9,877 and 7,212 human cases, respectively, during 2005 according to a March 2006 American Waterworks Association review article by P. Rochelle and J. Clancy. Testing conducted for Pure H2O Bio-Technologies, Inc., by Clancy Environmental Consultants, Inc. showed that activated tetrasilver tetraoxide (TTO) was effective as a disinfectant for both organisms. TTO is a unique divalent silver compound, which is produced in a crystalline form, with disinfectant properties superior to the common forms of silver. Joseph P. Doxey, president of Pure H2O Bio-Technologies, Inc. said: "The results show that the company can use this disinfectant as an alternative to those which are in current municipal and commercial use for drinking water treatment. Moreover, these studies on tetrasilver tetraoxide (patent pending) reported on July 1, 2005, Sept. 8, 2006 and October 25, 2006, respectively, are significant because Cryptosporidium oocysts are resistant to halogens such as chlorine and this pathogen has been known to escape state-of-the-art municipal water treatment systems and result in many human health outbreaks. E. coli although more easily disinfected, also has special significance as a waterborne and foodborne pathogen involved in recent outbreaks."
Reports from the Pure H2O Bio-Technologies studies of July 1, 2005 and October 25, 2006 showed that low concentrations of TTO, activated by two different oxidizing agents caused significant reductions in high concentrations of Cryptosporidium oocysts (highly resistant form of this waterborne parasite). The Sept. 8, 2006 study showed that activated/oxidized TTO caused more than a five-log10 reduction of E. coli (killed more than 100,000 bacteria) in 2 and 5 min. Thus, TTO can be incorporated into the contained drinking water disinfection system developed by Pure H20 Bio-Technologies and which will be submitted to the EPA verification conducted through NSF.
PHBT is a publicly held company specializing in the manufacturing, design and sale of its unique residential, commercial and hospital point-of-use potable water disinfection systems. These systems are specifically designed to work effectively against water-borne pathogens and remove heavy metals and objectionable biomass.
Note: The foregoing press release contains forward-looking statements that can be identified by such terminology as "expects," "potential," "suggests," "may," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development, and/or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and completion in general. Forward-looking statements speak only as to the date they were made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE: Pure H2O Bio-Technologies, Inc.
-------------------- Me Trade Pretty One Day. Posts: 815 | From: NYC | Registered: May 2006
| IP: Logged |
Big Scammer company. Stay away from this stock. .0001 is coming soon then they make a R/S again. They made a lot money by R/S over abd over again.
Posts: 115 | From: New York | Registered: Nov 2006
| IP: Logged |